Stockhub

CytoDyn Inc.: Revision history

View logs for this page

Diff selection: Mark the radio buttons of the revisions to compare and hit enter or the button at the bottom.
Legend: (cur) = difference with latest revision, (prev) = difference with preceding revision, m = minor edit.

2 September 2022

  • curprev 06:2706:27, 2 September 2022 95.149.241.133 talk 730 bytes +730 Created page with "== Summary<ref>Source: Yahoo Finance.</ref> == CytoDyn Inc. operates as a clinical-stage biotechnology company. The company focuses on developing treatments for multiple therapeutic indications based on leronlimab, a novel humanized monoclonal antibody targeting the CCR5 receptor in the areas of human immunodeficiency virus (HIV), non-alcoholic steatohepatitis (NASH), oncology, and such as coronavirus disease (“COVID-19”). It is also conducting a Phase 1b/2 clinical t..."
Retrieved from "https://stockhub.co/research/CytoDyn_Inc."